Terapia Génica del Cáncer
TGC
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (9)
2020
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2018
-
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain
Psycho-Oncology, Vol. 27, Núm. 6, pp. 1530-1537
2017
-
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
European Journal of Endocrinology, Vol. 177, Núm. 4, pp. 309-317
-
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience
Future Oncology, Vol. 13, Núm. 7, pp. 615-624
-
Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives
Gastroenterology, Vol. 153, Núm. 1, pp. 106-112.e2
2016
-
Endoscopic surveillance in patients with multiple (10-100) colorectal polyps
Endoscopy, Vol. 48, Núm. 1, pp. 56-61
2014
-
Prevalence and characteristics of mutyh-associated polyposis in patients with multiple adenomatous and serrated polyps
Clinical Cancer Research, Vol. 20, Núm. 5, pp. 1158-1168
2013
-
Clinical subtypes and molecular characteristics of serrated polyposis syndrome
Clinical Gastroenterology and Hepatology, Vol. 11, Núm. 6, pp. 705-711
2012
-
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
OncoImmunology, Vol. 1, Núm. 8, pp. 1344-1354